What a pharmacy can mix for you
How FDA rules limit GLOW peptide access
The three GLOW ingredients have withdrawn nominations, with FDA safety concerns still listed. Prescription care depends on a provider's decision and the rules for each patient.
Where GLOW stands under FDA rules
GLOW access and FDA approval are different questions. The blend is not FDA-approved.
FDA advisers met in July 2026 to discuss BPC-157 and TB-500. Their subject was the 503A list, which sets out ingredients a pharmacy may use for one named patient [14].
Advisers can make recommendations. Their meeting does not grant FDA approval or settle the final ingredient list [13][14].
The current FDA page puts GHK-Cu for injection, BPC-157 and the short TB-500 piece of thymosin beta-4 in its withdrawn-nominations table [12]. Their nominations were withdrawn, and FDA's safety concerns remain beside them [12].
Category 2 means the FDA sees a chance of serious safety trouble. Unlike Category 1, it does not promise to wait before acting against pharmacy use while the review continues [12][13].
Leaving Category 2 is not a move into Category 1. The ingredient rules still apply, and this change does not establish permission to compound these drugs [12][13].
What Category 2 means at a pharmacy
Federal law gives pharmacies two main ways to mix a drug. Section 503A covers a state-licensed pharmacy or doctor making medicine for one named patient with a valid order [13].
Section 503B covers an FDA-registered site that makes larger batches under tighter rules. Neither path lets a pharmacy choose any starting ingredient it wants [13].
That starting ingredient must pass one of three tests. It must appear in a trusted drug book, already be used in an FDA-approved drug, or sit on the FDA 503A list.
FDA advisers may discuss an ingredient that is still under review. Their advice matters, but the FDA makes the final choice.
The FDA once put waiting ingredients into numbered groups. Category 1 could sometimes be mixed while a review went on, but Category 2 did not get that break [12][13].
Other Category 1 items kept that break. The three GLOW parts entered the stricter group because of possible immune reactions, unwanted matter, and doubts about checking exactly what a peptide vial contains.
For you, that means both the ingredient and its quality worried the agency. The concern isn't just paperwork at a pharmacy.
On January 7, 2025, the FDA stopped adding newly named ingredients to these groups [12][13]. FDA now lists BPC-157, the TB-500 fragment and injectable GHK-Cu as nominated but withdrawn, with safety concerns still recorded beside each entry [12].
What the July meeting did and did not settle
The three GLOW parts don't all face the same rule, so the strictest limit matters for the blend. The July 2026 agenda named BPC-157 and TB-500 for discussion about the 503A ingredient list [14].
The meeting list names two chemical forms of BPC-157 and two forms of TB-500 [14]. The BPC-157 and TB-500 form names identify the versions on that agenda; they do not widen access.
The meeting notice does not establish a final listing decision. An advisory discussion alone does not change pharmacy rules [13][14].
GHK-Cu is different. The copper peptide is not on the July 2026 meeting list [14].
Injectable GHK-Cu is now listed among withdrawn nominations, with FDA's immune-reaction concerns still attached [12]. A cream used on skin faces a different rule.
In skin products, GHK-Cu is called Copper Tripeptide-1. Makeup and skin-care rules do not make that ingredient win FDA approval before sale [16].
That skin rule does not make a GHK-Cu shot approved. Withdrawal of the injectable nomination neither removes those safety concerns nor puts GHK-Cu in Category 1 [12][13].
What you and the pharmacy need before treatment
A sore knee or skin concern starts with a talk about your health, not a vial. GLOW care at Promise Peptides (mypromise.com) concerns GHK-Cu, BPC-157 and TB-500 together; its product needs a prescription, with a U.S.-licensed clinician assessing every request and making the prescribing decision. Not everyone qualifies. Care is limited to U.S. patients, and availability varies by state and treatment.
A video visit doesn't widen the ingredient list. You still need a real care tie and a valid order for one patient [13].
If the law allows the ingredient, the prescriber can send the order to a state-licensed 503A pharmacy, which mixes medicine for one patient. A registered 503B site may prepare larger batches as clinic stock [13].
The limit begins with the main ingredient before anything is mixed. Under 503A/503B rules, a withdrawn nomination does not by itself make an ingredient eligible for compounding [12][13].
This page explains the rule; it isn't medical or legal advice. Medicine Glow does not offer or supply peptides.
Is the GLOW blend legal now?
The parts do not share one legal status. Copper Tripeptide-1 may be used in skin products [16], but the FDA lists injectable GHK-Cu, BPC-157 and the TB-500 fragment among withdrawn nominations, with safety concerns still noted [12].
None is an FDA-approved drug. Each ingredient remains subject to compounding rules, even when a provider prescribes a blend [13].
May a pharmacy mix GHK-Cu for one patient?
FDA lists injectable GHK-Cu as nominated but withdrawn; that listing is not a finding that a pharmacy may use it under 503A [12][13]. Copper Tripeptide-1 on skin follows separate skin-care rules [16].
Where does GLOW stand under FDA 503A rules?
The FDA lists each main ingredient, not the blend as one drug. The FDA's withdrawn-nominations table contains GHK-Cu for injection, BPC-157 and the TB-500 fragment, along with its safety concerns [12].
BPC-157 and TB-500 appeared on the July 2026 advisory agenda [14]. A meeting is not a final FDA choice.
Why does the FDA restrict BPC-157?
The FDA previously placed BPC-157 in 503A Category 2 [12]. It cited possible immune reactions, unwanted matter, and trouble proving exactly what the drug contains.
BPC-157 has no FDA-approved use. FDA still records those concerns despite the withdrawn nomination [12].